ArticleHeart rhythm2020
Effects of hydroxychloroquine treatment on QT interval.
Article in Heart rhythm, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06816810 (TALLman Family Energizes Research To Help Alleviate Neuroinflammation in Parkinson's Disease - "TALLER THAN PD." A Phase 2 Futility Study to Evaluate the Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Early Treated Parkinson's Disease), which is not on this map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
TALLman Family Energizes Research To Help Alleviate Neuroinflammation in Parkinson's Disease - "TALLER THAN PD." A Phase 2 Futility Study to Evaluate the Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Early Treated Parkinson's Disease
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- COVID-19 related pressure injuries in patients and personnel: A systematic review.Journal of tissue viability · 2021Pooled it
- Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis.International journal of antimicrobial agents · 2020Pooled it
- Hydroxychloroquine to prevent SARS-CoV-2 infection among healthcare workers: early termination of a phase 3, randomised, open-label, controlled clinical trial.BMC research notes · 2023Trial
- Effect of hydroxychloroquine on the cardiac ventricular repolarization: A randomized clinical trial.British journal of clinical pharmacology · 2022Trial
- 2025 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus.Rheumatology and immunology research · 2025Article
- A Case Series and Review of Hydroxychloroquine Toxicity and Monitoring: How Do We Dose Hydroxychloroquine?Cureus · 2025Article
- Navigating data availability challenges in healthcare: assessing the added value of pulmonary function testing to the Care Assessment Need score for mortality risk.BMJ health & care informatics · 2025Article
- Hydroxychloroquine and the associated risk of arrhythmias.Global cardiology science & practice · 2024Review
- QTc Prolongation to Predict Mortality in Patients Admitted with COVID-19 Infection: An Observational Study.Current vascular pharmacology · 2024Observational
- Hydroxychloroquine in nephrology: current status and future directions.Journal of nephrology · 2023Review
- Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine-a possible prevention strategy for COVID-19?Molecular and cellular biochemistry · 2023Review
- A Review of Pathology and Analysis of Approaches to Easing Kidney Disease Impact: Host-Pathogen Communication and Biomedical Visualization Perspective : Advanced Microscopy and Visualization of Host-Pathogen Communication.Advances in experimental medicine and biology · 2023Review
- Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic.Current heart failure reports · 2022Review
- Biologic Functions of Hydroxychloroquine in Disease: From COVID-19 to Cancer.Pharmaceutics · 2022Review
- Risk Factors for QT Prolongation in Patients with Chronic Hydroxychloroquine Use.Acta Cardiologica Sinica · 2022Article
- Response to: 'Correspondence on 'Annals of the rheumatic diseases · 2022Article
- Hydroxychloroquine Blood Concentrations Can Be Clinically Relevant Also After Drug Discontinuation.Drugs in R&D · 2022Article
- Long-term safety and efficacy of hydroxychloroquine in patients with IgA nephropathy: a single-center experience.Journal of nephrology · 2022Article
- Article
- Increase in CaFrontiers in physiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHydroxychloroquine (HCQ) has been promoted as a potential treatment of coronavirus disease 2019 (COVID-19), but there are safety concerns.
objectiveThe purpose of this study was to determine the effects of HCQ treatment on QT interval.
methodsWe retrospectively studied the electrocardiograms of 819 patients treated with HCQ for rheumatologic diseases from 2000 to 2020. The primary outcome was corrected QT (QTc) interval, by Bazett formula, during HCQ therapy.
resultsMean patient age was 64.0 ± 10.9 years, and 734 patients (90%) were men. Median dosage of HCQ was 400 mg daily, and median (25th-75th percentile) duration of HCQ therapy was 1006 (471-2075) days. Mean on-treatment QTc was 430.9 ± 31.8 ms. In total, 55 patients (7%) had QTc 470-500 ms, and 12 (1.5%) had QTc >500 ms. Chronic kidney disease (CKD), history of atrial fibrillation (AF), and heart failure were independent risk factors for prolonged QTc. In a subset of 591 patients who also had a pretreatment electrocardiogram, mean QTc increased from 424.4 ± 29.7 ms to 432.0 ± 32.3 ms (P <.0001) during HCQ treatment. Of these patients, 23 (3.9%) had either prolongation of QTc >15% or on-treatment QTc >500 ms. Over median 5.97 (3.33-10.11) years of follow-up, 269 patients (33%) died. QTc >470 ms during HCQ treatment was associated with a greater mortality risk (hazard ratio 1.78; 95% confidence interval 1.16-2.71; P = .008) in univariable but not in multivariable analysis.
conclusionHCQ is associated with QT prolongation in a significant fraction of patients. The risk of QT prolongation is higher among patients with CKD, AF, and heart failure, who may benefit from greater scrutiny.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.